216 related articles for article (PubMed ID: 12957298)
1. Iron as a co-morbid factor in nonhemochromatotic liver disease.
Bonkovsky HL; Lambrecht RW; Shan Y
Alcohol; 2003 Jun; 30(2):137-44. PubMed ID: 12957298
[TBL] [Abstract][Full Text] [Related]
2. Iron in nonhemochromatotic liver disorders.
Alla V; Bonkovsky HL
Semin Liver Dis; 2005 Nov; 25(4):461-72. PubMed ID: 16315139
[TBL] [Abstract][Full Text] [Related]
3. Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis.
Bonkovsky HL; Obando JV
Curr Gastroenterol Rep; 1999; 1(1):30-7. PubMed ID: 10980924
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection.
Toll A; Celis R; Ozalla MD; Bruguera M; Herrero C; Ercilla MG
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1201-6. PubMed ID: 17062032
[TBL] [Abstract][Full Text] [Related]
5. [Role of the hemochromatosis gene in prophyria cutanea tarda. Prospective study of 56 cases].
Skowron F; Bérard F; Grézard P; Wolf F; Morel Y; Perrot H
Ann Dermatol Venereol; 2001 May; 128(5):600-4. PubMed ID: 11427792
[TBL] [Abstract][Full Text] [Related]
6. Association of porphyria cutanea tarda with hereditary hemochromatosis.
Mehrany K; Drage LA; Brandhagen DJ; Pittelkow MR
J Am Acad Dermatol; 2004 Aug; 51(2):205-11. PubMed ID: 15280838
[TBL] [Abstract][Full Text] [Related]
7. Iron overload in porphyria cutanea tarda.
Sampietro M; Fiorelli G; Fargion S
Haematologica; 1999 Mar; 84(3):248-53. PubMed ID: 10189391
[TBL] [Abstract][Full Text] [Related]
8. HFE mutations and transferrin receptor polymorphism analysis in porphyria cutanea tarda: a prospective study of 36 cases from southern France.
Dereure O; Aguilar-Martinez P; Bessis D; Perney P; Vallat C; Guillot B; Blanc F; Guilhou JJ
Br J Dermatol; 2001 Mar; 144(3):533-9. PubMed ID: 11260010
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of hemochromatosis-related HFE C282Y/H63D gene mutations in patients on chronic dialysis.
Canavese C; Bergamo D; Barbieri S; Timbaldi M; Thea A; Martina G; Damiani D; Fenoglio R; Donati-Marella B; Priolo G
Clin Nephrol; 2002 Dec; 58(6):438-44. PubMed ID: 12508966
[TBL] [Abstract][Full Text] [Related]
10. Iron-induced liver injury.
Bonkovsky HL; Lambrecht RW
Clin Liver Dis; 2000 May; 4(2):409-29, vi-vii. PubMed ID: 11232198
[TBL] [Abstract][Full Text] [Related]
11. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron.
Wallace DF; Subramaniam VN
Biochim Biophys Acta; 2009 Jul; 1790(7):663-70. PubMed ID: 18848602
[TBL] [Abstract][Full Text] [Related]
12. Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis.
Valenti L; Dongiovanni P; Fracanzani AL; Santorelli G; Fatta E; Bertelli C; Taioli E; Fiorelli G; Fargion S
Dig Liver Dis; 2003 Mar; 35(3):172-8. PubMed ID: 12779071
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of HFE gene mutations in patients with porphyria cutanea tarda in the Czech Republic.
Kratka K; Dostalikova-Cimburova M; Michalikova H; Stransky J; Vranova J; Horak J
Br J Dermatol; 2008 Sep; 159(3):585-90. PubMed ID: 18565178
[TBL] [Abstract][Full Text] [Related]
14. Iron and liver diseases.
Fargion S; Mattioli M; Fracanzani AL; Fiorelli G
Can J Gastroenterol; 2000 Nov; 14 Suppl D():89D-92D. PubMed ID: 11110619
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda.
Sampietro M; Piperno A; Lupica L; Arosio C; Vergani A; Corbetta N; Malosio I; Mattioli M; Fracanzani AL; Cappellini MD; Fiorelli G; Fargion S
Hepatology; 1998 Jan; 27(1):181-4. PubMed ID: 9425935
[TBL] [Abstract][Full Text] [Related]
16. Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C.
Azim J; McCurdy H; Moseley RH
World J Gastroenterol; 2008 Oct; 14(38):5913-5. PubMed ID: 18855993
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of the hemochromatosis gene mutation in patients with nonalcoholic steatohepatitis and correlation with degree of liver fibrosis.
Zamin I; Mattos AA; Mattos AZ; Migon E; Bica C; Alexandre CO
Arq Gastroenterol; 2006; 43(3):224-8. PubMed ID: 17160239
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis.
Bonkovsky HL; Jawaid Q; Tortorelli K; LeClair P; Cobb J; Lambrecht RW; Banner BF
J Hepatol; 1999 Sep; 31(3):421-9. PubMed ID: 10488699
[TBL] [Abstract][Full Text] [Related]
19. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.
Valenti L; Fracanzani AL; Bugianesi E; Dongiovanni P; Galmozzi E; Vanni E; Canavesi E; Lattuada E; Roviaro G; Marchesini G; Fargion S
Gastroenterology; 2010 Mar; 138(3):905-12. PubMed ID: 19931264
[TBL] [Abstract][Full Text] [Related]
20. HFE gene in primary and secondary hepatic iron overload.
Sebastiani G; Walker AP
World J Gastroenterol; 2007 Sep; 13(35):4673-89. PubMed ID: 17729389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
